Skip to main content

GRFS

Stock
Health Care
Drug Manufacturers - General

Performance overview

GRFS Price
Price Chart

Forward-looking statistics

Beta
1.63
Risk
56.44%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.

Company info

SectorHealth Care
IndustryDrug Manufacturers - General
Employees17K
Market cap$4.9B

Fundamentals

Enterprise value$21.0B
Revenue$8.7B
Revenue per employee—
Profit margin2.65%
Debt to equity121.14

Security info

ExchangeNASDAQ
Type of shareADR
Earnings per share (EPS)$0.27
Dividend per share$0.91
Revenue per share$5.42
Avg trading volume (30 day)$6M
Avg trading volume (10 day)$6M
Put-call ratio—

Macro factor sensitivity

Growth+2.0
Credit+0.4
Liquidity+0.1
Inflation+0.5
Commodities+1.2
Interest Rates-0.6

Valuation

Dividend yield10.06%
PEG Ratio8.11
Price to sales1.03
P/E Ratio8.11
Enterprise Value to Revenue2.42
Price to book1.10

Upcoming events

Next earnings dayMay 12, 2025
Next dividend day—
Ex. dividend dayJune 3, 2021

News

Grifols (GRFS) Is Up 2.47% in One Week: What You Should Know

Does Grifols (GRFS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research (June 5, 2025)
Why Is Spanish Healthcare Grifols Stock Trading Lower On Friday?

On Wednesday, Grifols SA GRFS said it ended discussions with Brookfield Capital Partners (UK) Limited about a potential acquisition.

Benzinga (November 29, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free